8-K

UNITED STATES

SECURITIES AND EXCHANGECOMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2013

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts	000-21615	04-2652826
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14 Norfolk Avenue

South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

The Company presented at the SeeThruEquity Investor Conference in New York City on November 12, 2013.

The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 2.02 as if fully set forth herein.  

On November 18, 2013, the Company issued a press release announcing business and financial updates. A copy of the release is furnished herewith as Exhibit 99.2.

The information contained in this Current Report, including Exhibits 99.1, 99.2 are being furnished and not filed pursuant to this Item 2.02 of Form 8-K. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Company information – “Power Point Presentation” dated November 12, 2013 (filed herewith).
99.2	Press Release, dated November 18, 2013, relating to Pressure BioSciences’ financial results (filed herewith).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRESSURE BIOSCIENCES, INC.
Date:  November 18, 2013	By:	/s/ Richard T. Schumacher
		Richard T. Schumacher President and Chief Executive Officer

3

EX-99.1

Investor Presentation

Pressure BioSciences, Inc.
(OTCQB: PBIO)
Discovery Starts
with Sample Preparation™
Richard T. SchumacherPresident & CEO
rschumacher@pressurebiosciences.com

SeeThruEquity NYC
November 12, 2013

Forward Looking Statements

This presentation may contain forward looking statements
that reflect management’s current views and opinions as
to the status of the Company’s products, technology and
other future events and operations.These statements are
neither a promise nor guarantee, but involve risks and
uncertainties that could cause actual results to differ
materially from those anticipated or indicated.Investors
are cautioned that any forward looking statements should
be considered in light of such risks and uncertainties
including, without limitation, those detailed in the
Company’s filings with the

Securities and Exchange Commission.

2

•Pressure Cycling Technology (PCT): Powerful, Enabling, Patented

•Primary Application: Sample Preparation ($ Billion Market Opportunity)

•PCT Products Offer Significant Advantages Over Competitive Methods

•Proven Technology: ~ 235 Installations in ~150 Marquee Laboratories

•Attractive “Razor/Razorblade” Business Model

•On-going Discussions with Large Potential Strategic Partners

•Experienced Management Team and Board of Directors

•Favorable Market Valuation for the Investor

•Active Commercialization of PCT Platform Has Begun

•Two Recent Technical Breakthroughs Reported

•Record Revenue Reported Q3 2013; Strong Guidance for Q4 2013

Key Investment Highlights

3

•Formed Sept 2004 - Sale of Boston Biomedica (BBII)

•Started Operations in 2006

•OTCQB: PBIO

•Ten (10) Full-time Employees

•Strong Management Team and Board of Directors

•Focused on the Development and Commercialization of
PCT-based Instruments and Consumables for the Preparation
of Biological Samples for Research Laboratories

•Strong IP - 24 Issued PCT Patents with More Pending

*

Company Background

Historical Revenue Data

•FY 2011$988,000

•FY 2012$ 1,256,000

•FY 2013 (thru Q3)$ 1,150,000

Selected Data:November 11, 2013

•Cash/AR~$ 0.28 million

•Inventory~$ 0.87 million

•Debt (other than AP)$ 450K

Selected Data:September 13, 2013

•Common O/S11.9 million

•Preferred (common equiv)8.3million

Total CSs and CS Equiv O/S20.2million

•Warrants & Options13.0 million ($0.40 - $3.00)

•Price per Share$ 0.21

•Market Cap (Com/Pfd)$ 4.2million

Financial Data

5

Management

•Mr. Richard T. Schumacher, President & CEO

Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder);

Trinity Biotech (Founding Group); CBR Labs (Gen’l Mgr) - Harvard Medical School

•Dr. Edmund Y. Ting, Senior Vice President of Engineering

Avure Technologies (CSO); Flow Int’l (CSO); Grumman Aerospace; MIT (Ph.D.)

•Dr. Alexander V. Lazarev, Vice President of R&D

Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)

•Dr. Nathan P. Lawrence, Vice President of Marketing

Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)

•Mr. Conrad Mir,Chief Financial Officer

Genetic Immunity (CEO); Advaxis; Sanford Bernstein; First Liberty; Nomura

Board

•Jeffrey Peterson, MBA, Chairman

•Kevin Pollack, Esq., MBA, Audit Committee Chairman

•Vito Mangiardi, MBA, Compensation Committee Chairman

•Mickey Urdea, Ph.D.,SAB Chairman

•Richard T. Schumacher

*

Experienced Senior Management & Board

•Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is
Crucial to the Development of New Diagnostics & Therapeutics

•Sample Preparation is Required Prior to Virtually All Analyses

•Current Sample Preparation Methods Highly Inadequate: bottleneck

•PCT Offers Clear Advantages Over Current Competitive Products

•Current Target: Life Sciences Research Market - minimal regulatory

•PBI Holds 24 Issued PCT Patents in Multiple Sample Prep Applications

•Early Traction…about 235 PCT Systems installed through Q1 2013

•$6 Billion Market Opportunity for Sample Preparation Products***

•~ 500K Scientists in ~ 80K Labs WW require sample preparation

• *Strategic Directions Int’l;**The Emmes Group

*

Value Proposition - Sample Prep Market

Release Important Biomolecules by Cell Lysis

8

Scientific research can be broken down to three key elements:

sample preparation, analysis, & data reduction/interpretation

“Discovery Starts with Sample Preparation”

Sample Input Quality=Sample Result Quality

9

Competitive Landscape

•Mortar & Pestle

•Dounce homogenizer (glass on glass)

•Potter-Elvenhjem homogenizer (Teflon on glass)

•Enzymatic Digestion

•Polytron shearing homogenizers

•Blenders

•Bead Beating

•Sonication

•Repeated Freeze/Thaw cycles

•French Press (≤ 2000 PSI)

Mostly Commodity Products Through Catalogue Sales

10

Barocycler™
NEP2320

PCTSample Preparation System

11

PULSE Tube

MicroTubes

PCT-dependent Kits

Next Gen PCT Platform:HUB Family of Barocyclers

High Pressure Generators

for Multiple Research & Mfg Applications

•Compact

•Portable

•Versatile

•Computer Controlled

•Labview Software Driven

•Pressures to:

• 20 kpsi(HUB160) 2012

• 60 kpsi(HUB440) 2012

• 100 kpsi (HUB880) Q12014

12

…the HUB for every laboratory’s high pressure needs via

state-of-the-art, application specific modules & software

Product Pipeline (2011 Release)

The Shredder SG3

Low Shear, Mechanical, Homogenization
Device

Long lasting lithium

rechargeable batteries

Paddle for convenient

pressure setting

Pressure force levels:

15, 30, 45 lbs. Force

Uses PCT PULSE and

Shredder Tubes

Heavy Duty, Robust Driver

Cole Parmer, a Thermo Fisher Company, and
a Major Worldwide Distributor of Lab
Products, Announced in Oct 2012 that They
will Distribute the Shredder SG3

13

Selected Marquee Customers (40 of 150)

•Amgen

•Biogen

•Lilly

•Novartis

•Monsanto

•BM Squibb

•Merck

•Centocor

•Takeda Pharmaceuticals

•Momenta Pharmaceuticals

•US Army

•FBI

•Food and Drug Administration

•US Departmentof Agriculture

•National Institutes of Health

•Armed Forces Inst. of Pathology

•Centers for Disease Control

•USAMRIID

•Dana Farber Cancer Center

•Burnham Research Institute

•Thermo Fisher

•Target Discovery

•Battelle Memorial Institute

•Harvard Medical School

•Harvard School of Public Health

•Rockefeller University

•University of New Hampshire

•Barnett Research Inst (NEU)

•UCLA

•UC - San Diego

•UC - Davis

•Lawrence Livermore

•Stanford University

•University of North Texas

•Mississippi State

•Montana State

•Lawrence Berkeley

•University of Kentucky

•Florida Int’l University

•UMASS - Boston

14

High Level Overview of Current Fields of Use and Applications for PCT:

a Few Select Examples

15

Proteomics (Proteins)

•Biomarker Discovery:Heart Disease and Cancer

•Pressure-Enhanced Enzymology:Trypsin and Deglycosylation

•Enhance/Enable Protein Analysis:Mass Spectrometry, EPR, ESR, and NMR

•Enhance Protein Extraction from FFPE:Diagnostics and Drug Development

•Biopharmaceuticals, Vaccines, and Biosimilars:Discovery, Synthesis and QC

Genomics (DNA, RNA)

•Forensics:Rape Kit Analysis, Bone, and Touch Samples

•Enhance DNA Sequencing:DNA Shearing

•Agriculture:HLB Disease (Greening Disease in Citrus) and Soil Pathogens

•Environmental Biology:Oil Eating Bacteria

•Antibioterror:Rapid Identification and Inactivation

Transcriptomics (RNA):Gene Expression and Drug Discovery

Lipidomics (Fats):Lipid Analysis of fecal material, Metabolomic Diseases, E.g. Diabetes

Mitochondria:Mitochondrial-related Diseases E.g. MDys, Autism,C .Palsy

Food:Pathogen testing, Manufacturing

Herbal Medicine:Discovery, Manufacturing

Chemical:High Pressure Chemical Syntheses and Analysis

Industrial Applications:Automotive, Oil Well Discovery and Recovery

PCT Focus Area: Biomarker Discovery

Dr. Andreas Huhmer - Thermo Fisher Scientific

…advantages of speed and quality using PCT in mass specworkflow

Dr. Michael Alterman - Tumor Vaccines and Biotechnology Branch, CBER, FDA

…improved influenza vaccine quality using PCT in mass spec workflow

Dr. Alexander Ivanov - Harvard School of Public Health

…improved membrane protein identification using PCT in mass spec workflow

Dr. Bruce McCord, Florida International University

…improved processing of forensic (rape kit) samples using PCT

Dr. Luke Schneider, Target Discovery, Inc.

…improved membrane protein recovery in ovarian cancer studies using PCT in mass spec workflow

Dr. Bruce Budowle, Health Science Center, University of North Texas

…improved detection of DNA in forensic samples using PCT

Forensics

Cancer, Heart Disease, Inf. Diseases, Neurological Disorders, Etc.

Dr. Henry C. Lee, the Henry C. Lee Institute of Forensic Science

…evaluation of PCT in the recovery and detection of DNA in difficult forensic samples

Dr. Jeff Mason and Dr. Carol Fowler, Armed Forces Institute of Pathology

...improved processing of FFPE (histology) samples using pressure

Dr. Jennifer Van Eyk, Johns Hopkins School of Medicine

…improved recovery of aorta proteins from FFPE samplesusing PCT

16

Professor Wayne Hubbell- UCLA

"Protein flexibility is the new frontier in understanding protein
function and regulation. The study of proteins under pressure
has great ability to reveal salient features of protein flexibility,
and hence provide new insights into protein function and
rational drug design.In my opinion, high pressure will
play a central role in the discovery process that lies ahead in
the exciting field of protein science, and PBI’s PCT Product
Linewill make major contributions to this field.”

December, 2012

17

Distinguished Professor of
Chemistry & Biochemistry,
and Jules Stein Professor at
UCLA

Dr. Henry C. Lee

“We are excited about this opportunity to collaborate with
Pressure BioSciences to examine the potential applications of
their PCT Platform in improving the collection of forensic
evidence, particularly DNA, in several important areas of
forensics…such collaborations not only provide new, effective
technologies for forensic DNA testing of samples that have
been difficult or unsuitable using today’s standard techniques,
but can also provide new and more effective ways to
reexamine old biological evidence in cold cases.”

18

Professor of Forensic Science and
founder of the Forensic Science
Program at the University of New
Haven; founder of the HC Lee
Institute of Forensic Sciences; and
former Commissioner of Public
Safety for the State of Connecticut.

2013 News of Interest

•PBI Reports Record Financial Results (revenue) forQ3 2013

Guidance Given for Strong Q4 2013 Revenue

Guidance Given on Two New Instrument Systems (Q1 and Q2 2014)

•PBI Announces Close of $2.0 Million Above-Market Private Placement

•Core Technology Breakthrough Announced

•Novel Method Published for Lipid Analysis in Fecal Material Using PCT

•Further Advances Reported in Improved Rape Kit Testing Method Using PCT

•Dr. Mickey Urdea Joins Board (Feb 2013); Pollack & Mangiardi in July 2012

•Sales Reach Expanded to Approximately 20 Countries Over Past Year

•PBI and Constant Systems Announce Strategic Partnership

•Improvements in DNA Yield from Forensic Samples Reported

19

2013 Key Product Drivers (High Throughput PCT)

• Breakthrough in Core PCT Technology Platform - High Throughput
a) announced on June 4, 2013
b) will allow PCT sample processing with universal, high throughput multiwell format
c) will allow PCT Systems to integrate with HT instruments in thousands of labs WW
d) is expected to significantly accelerate discussions with potential strategic partners
e) is expected to have significant impact on PBI’s revenue growth, starting Q2 2014


Barocycler HUB880 -pressure up to 100,000 psia) first of its kind
b) will allow scientists to go to 100,000 psi
c) Q1 2014 release
• Novel PCT-based Method for Lipid Analysis in Fecal Material
a) announced on May 16, 2013
b) collaboration with Dr. Bruce Kristal and Team at HMS and B/W Hospital, Boston
c) could provide a reproducible, generally applicable, broad-based, non-invasive
technique for establishing GI function in patients regardless of age/disease
d) could significantly impact diagnosis, treatment, cure, and prevention of
GI diseases/disorders, e.g., colon cancer, inflammatory bowel disease, obesity
e) could offer new paradigm for nutritional, infectious, & inflammatory status

20

2013 Potential Drivers

21

2013 Potential Drivers:High Throughput PCT

Automated liquid handling helps ensure accuracy and reproducibility,
eliminates repetitive tasks, and frees personnel for other activities.

22

HT PCT Product Concept

2013 Potential Drivers:High Throughput PCT

23

2013 Potential Drivers:High Throughput PCT

Beta Units Ready for Testing: February 2014

Beta Site Evaluation Completed: April2014

Commercialization: June 2014

Initial Applications
•rapid protein digestion (multiple labs, worldwide)
•lipid profiling (multiple diseases/disorders of the GI tract)

HTP PCT Platform
•will use new Barocycler HUB or modified instruments
•will use new accessories and modules
•will use new multiwell plate consumables
•will use liquid handling automation, e.g., LEAP Technologies

Strategic Partnerships:Discussions Have Been
Accelerated

24

EX-99.2

FOR IMMEDIATE RELEASE

Investor Contacts: Richard T. Schumacher, President & CEO,    Richard P. Thomley, Acting Chief Financial Officer      (508) 230-1828 (T)

Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue,

Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems,

and Expectation to Pay-Off All Outstanding Convertible Notes

at the SeeThruEquity Financial Conference

South Easton, MA, November 18, 2013 -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”) today announced that Mr. Richard T. Schumacher, the Company’s President and CEO, presented a business and financial update on the Company at the November 12th SeeThruEquity Investor Conference in New York City.

Among the topics discussed by Mr. Schumacher were:

● the Company’s all-time record quarterly revenue, as reported in the fiscal 2013 third quarter;

● revenue and earnings guidance for the fourth quarter of fiscal 2013 to date (Mr. Schumacher disclosed that the Company’s product revenue through the first five weeks of its current fiscal fourth quarter  has already  surpassed product revenue for the entire fourth quarter of fiscal 2012).

● the significant progress made by the Company in the development of its Barocycler HUB880 and the Barocycler High Throughput (microwell) pressure cycling technology (“PCT”)-based instrument systems, and the expectation for the products’ Q1 2014 and Q2 2014 commercial releases, respectively.

● the expectation for the Company to  repay all outstanding convertible notes prior to maturity.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We believe that our financial condition will be materially better by years’ end than it has been for several years, due to the expected repayment of all convertible notes currently outstanding, combined with expected strong F2013 Q4 operating results, new debt under more favorable terms, and an anticipated fiscally-responsible equity infusion.”

Mr. Schumacher continued, “With the expected launch of two new instrument systems during the first half of next year, both of which are expected to add significantly to 2014 revenue, and our continued vigilance in keeping expenses in check, we believe our financial health will only get stronger going forward.”

Mr. Douglas Rogers, Managing Director and Head of the Capital Markets Advisory Group of Merriman Capital, Inc. said: “We are very impressed with the progress that the PBI Team has made in 2013, much of which we have observed first-hand as PBI is an advisory client of ours.  During this time, they seem to have successfully reached a number of management’s key milestones, including record quarterly revenue and an apparent breakthrough in their patented pressure cycling technology (“PCT”) platform.  We believe the PCT platform could be one of the most compelling new technology platforms we have seen in the space, and we will continue to help support management and the Company as it seeks to leverage its recent performance.”

A link to a webcast of Mr. Schumacher’s presentation can be found below and on the home page of the Company’s website. http://wsw.com/webcast/seethru5/pbio

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”).  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market.  PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.  PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

                                                          For more information about PBI and this press release, please click on the following website link:

                                                 Please visit us on: Facebook, LinkedIn, and Twitter.

                                                             http://www.pressurebiosciences.com